×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
COGT – cogent biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
COGT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
08:21 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/11
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.
12/9
08:11 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
High
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
12/9
07:00 am
cogt
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Medium
Report
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
12/8
12:00 pm
cogt
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Medium
Report
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/4
01:17 pm
cogt
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
11/14
01:34 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
11/13
08:06 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/9
04:02 pm
cogt
Form 8-K Cogent Biosciences, Inc. For: Dec 08
Low
Report
Form 8-K Cogent Biosciences, Inc. For: Dec 08
11/14
08:00 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
High
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
11/14
05:47 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
High
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
11/14
04:06 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: COMMODORE CAPITAL LP
11/14
03:53 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Low
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
11/14
12:25 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP
Low
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP
11/12
09:46 am
cogt
Form 10-Q Cogent Biosciences, Inc. For: Sep 30
Low
Report
Form 10-Q Cogent Biosciences, Inc. For: Sep 30
11/12
09:36 am
cogt
Form 8-K Cogent Biosciences, Inc. For: Nov 12
Low
Report
Form 8-K Cogent Biosciences, Inc. For: Nov 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: